Search

everythinglearnresearchcommunity

for

Search:↓

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The user is considering adding low-level laser therapy (LLLT) to their hair loss treatment routine, which already includes minoxidil, finasteride, and microneedling. They are debating between purchasing a cheaper LLLT device or investing in a more expensive, clinically-backed option, with concerns about the effectiveness and specifications of cheaper models.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

A 24-year-old experiencing severe hair thinning has been using minoxidil for 2 years but is still shedding hair. A doctor recommended plasma treatment over a DHT blocker for better and healthier results.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.

A 24-year-old is considering a hair transplant but is hesitant due to cost and finding his shaved head looks better than expected. He plans to try finasteride to improve hair density after unsuccessful attempts with minoxidil and dutasteride.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Hair loss discussion includes DIY HMI-115 and its high cost (20-30k per person). Minoxidil, finasteride, and RU58841 mentioned as treatments.

A 24-year-old tried minoxidil, finasteride, keto shampoo, and derma-rolling for hair loss but saw no improvement and is now at Norwood 5. They feel there's nothing more they can do and are considering going bald despite not liking the look.

Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.

Finasteride and Nizoral shampoo with Ketoconazole are used for hair loss treatment. Liquid Chromatography–Mass Spectrometry (LC-MS) is recommended over Enzyme-Linked Immunosorbent Assay (ELISA) for more accurate DHT testing.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation is about a group of people trying KX-826 for hair loss, with no serious side effects reported after 25 days of use. Some participants are experiencing less scalp itch and shedding, but it's too early for definitive results.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.